Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by etocron Jun 08, 2006 12:26pm
136 Views
Post# 10963147

I hope I'm wrong but...

I hope I'm wrong but...The latest court filing by PricewaterhouseCoopers said the purchase by 2092248 Ontario requires reaching an accord by June 20 with ProMetic Bioscience Ltd. of Montreal to continue licensing its cascade technology to strip therapeutic proteins from blood plasma at Hemosol's plant in Mississauga. What I understand of it is not an obligation to use cascade in the transaction. If Melnyk want to buy the plant without using cascade, we will have nothing. But, if he want, we'll have some fees and gel sale.
Bullboard Posts